Medical cannabis report released by Veriheal

The latest medical cannabis report was released Tuesday by a company that is one of the biggest facilitators of medical marijuana cards in the U.S. The company examined the health goals and preferences of U.S. medical marijuana MMJ patients using segmented survey data.

In order to create the report, Veriheal teamed up with members of NORML, the University of Maryland School of Pharmacy and the University of California, LA, which collected information from 200,000 anonymized adult patients who signed up for an appointment with an MMJ doctor using Veriheal's platform in 2022. Patients answered assorted questions regarding their medical needs and use of cannabis.

Anthony Dutcher, Veriheal CMO, stated that Veriheal is committed to helping the medical cannabis industry serve all patients with the help of data-driven intelligence.

The study also examined whether state cannabis legalization status affects patient product preferences, as well as the use of older patients for the purpose of treating chronic pain 58%, while younger generations tend to use it to improve sleep 64%. Additional research points to product availability and advertising practices as factors in patient preferences.